Cantor Fitzgerald Reiterates “Overweight” Rating for Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a report released on Monday, Benzinga reports.

A number of other equities analysts have also recently weighed in on the company. Evercore ISI restated an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a report on Monday, August 26th. BTIG Research assumed coverage on shares of Jasper Therapeutics in a report on Monday, July 8th. They set a “buy” rating and a $90.00 price target for the company. Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th. Stifel Nicolaus initiated coverage on Jasper Therapeutics in a research note on Thursday, June 27th. They set a “buy” rating and a $86.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, August 13th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Jasper Therapeutics currently has an average rating of “Buy” and an average target price of $73.00.

Jasper Therapeutics Stock Up 4.7 %

Shares of JSPR stock traded up $0.87 on Monday, reaching $19.50. 66,357 shares of the stock were exchanged, compared to its average volume of 138,846. Jasper Therapeutics has a 1-year low of $4.00 and a 1-year high of $31.01. The stock has a market cap of $294.45 million, a P/E ratio of -3.46 and a beta of 2.22. The firm has a 50 day moving average of $19.59 and a two-hundred day moving average of $22.68.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.12. On average, equities research analysts predict that Jasper Therapeutics will post -4.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Jasper Therapeutics

Large investors have recently added to or reduced their stakes in the company. Ieq Capital LLC bought a new position in shares of Jasper Therapeutics in the 4th quarter worth about $43,000. Rhumbline Advisers bought a new position in Jasper Therapeutics in the second quarter worth about $300,000. Virtu Financial LLC acquired a new position in Jasper Therapeutics in the first quarter valued at approximately $306,000. American Century Companies Inc. grew its holdings in shares of Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after purchasing an additional 3,032 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in shares of Jasper Therapeutics during the first quarter valued at approximately $599,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.